FDA Rejects Summit's Ivonescimab, Citing Lack Of Statistically Significant Overall Survival Benefit
By Elizabeth Urbanek, Executive Editor

The FDA won't approve Summit Therapeutics' ivonescimab in previously treated lung cancer until the company shows the drug helps patients live longer. Slowing tumor growth, the agency said, isn't enough on its own. That's a setback for Summit and its partner, Akeso — and a signal worth reading for every company developing a bispecific antibody that targets PD-1 and vascular endothelial growth factor (VEGF).
Announced Nov. 15, Summit said the agency issued a complete response letter (CRL) on its biologics license application (BLA) for ivonescimab plus platinum-containing chemotherapy. The filing sought approval in locally advanced or metastatic non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
The sticking point was overall survival (OS). According to Summit, the FDA said substantial evidence of effectiveness isn't established without a statistically significant OS improvement. A progression-free survival (PFS) benefit alone, the agency added, doesn't support a positive benefit-risk profile.
Summit's pivotal Phase 3 HARMONi trial hit its PFS primary endpoint. OS trended the right way in the primary analysis but fell short of statistical significance. A later post hoc analysis, with more follow-up, put the hazard ratio at 0.76 in the full population, in Asian patients, and in Western patients.
Summit says development will continue. The program includes HARMONi-3 in first-line metastatic NSCLC and HARMONi-7, which tests ivonescimab on its own. There are also studies in colorectal, urothelial, kidney, head and neck, and biliary tract cancers, plus combination work with several other drugmakers. Ivonescimab has been approved in China since May 2024.
What the release leaves out matters, too. Summit didn't say whether it will resubmit, didn't offer dates for readouts or filings, and didn't mention any manufacturing or product-quality problems. It also doesn't say how the FDA's position might carry over to other indications or other PD-1xVEGF drugs.
What This Means For Clinical Supply
For supply teams, the issue here is the calendar. Trials that need survival data run until enough events accrue, and OS takes longer to mature than PFS. If sponsors in this class decide they need mature OS before they file, patients may stay on treatment — and in follow-up — well past what the original supply plan assumed.
Longer studies use more of everything: investigational medicinal products (IMPs), comparators such as pembrolizumab, and the chemotherapy backbone. They also push inventory past expiry dates set when the study started. That usually means more shelf-life extensions, more relabeling, and more lot changes, often late in a study, when sites have the least patience for them.
There's no free option. Make IMP and buy comparator for the longer horizon, and you protect continuity but tie up budget — and you risk write-offs if the trial stops early or the protocol changes. Stick with the original forecast, and you save money but leave yourself less room if the timeline slips.
Part of the problem is that supply doesn't own the duration assumption. Biostatistics and regulatory usually do. But forecasting, comparator sourcing, the CMC (chemistry, manufacturing, and controls) teams that own stability data, and the expiry settings in interactive response technology (IRT) systems all depend on it. Supply teams should find out which timeline today's plan reflects and push for a range of scenarios instead of a single date.
A caveat: Nothing in Summit's announcement says any sponsor will extend a trial. The CRL covers one indication and one data package, and the FDA hasn't issued class-wide guidance. Whether this ripples across other PD-1xVEGF programs is still an open question, and each team will have to answer it against its own regulatory strategy.
So for anyone supplying a PD-1xVEGF program, the question is simple to ask and harder to answer: Does the plan still hold if the filing waits for overall survival instead of progression-free survival?
The Supply Question
Do you fund supply for a longer, survival-driven trial now, or hold the forecast and take the late-stage risk?
Related Clinical Supply Leader Editorials:
- An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
- The Operational Challenge Of Concurrent Shelf Life Extensions
- How A Comparator Is Really Bought
About The Author:
Elizabeth Urbanek is the Executive Editor for Clinical Supply Leader, where she works with clinical trial supply and logistics professionals across pharma and biotech to bring real-world perspectives, operational challenges, trends, scientific insights and regulatory strategy to the field.
Before joining life sciences media, Elizabeth spent more than 15 years in broadcast, digital and live-event storytelling, helping highly technical teams communicate complex ideas with clarity and impact. She brings that same approach to clinical supply, creating editorial space for experts to share what is happening across clinical trial operations.
Elizabeth is passionate about connecting people and ideas, identifying emerging themes and showcasing work that can move the clinical supply field forward.